| 1.69 -0.16 (-8.65%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.24 | 1-year : | 2.51 |
| Resists | First : | 1.92 | Second : | 2.15 |
| Pivot price | 1.76 |
|||
| Supports | First : | 1.55 | Second : | 1.29 |
| MAs | MA(5) : | 1.82 |
MA(20) : | 1.76 |
| MA(100) : | 1.61 |
MA(250) : | 2.15 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 43.5 |
D(3) : | 48.7 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 5.09 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MGNX ] has closed above bottom band by 33.7%. Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.87 | 1.87 - 1.88 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Wed, 22 Oct 2025
MacroGenics, Inc. (NASDAQ:MGNX) institutional owners may be pleased with recent gains after 49% loss over the past year - Sahm
Sat, 18 Oct 2025
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results - ADVFN
Fri, 05 Sep 2025
MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) - Seeking Alpha
Tue, 02 Sep 2025
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Thu, 21 Aug 2025
Director William Heiden Acquires 100,000 Shares of Macrogenics I - GuruFocus
Sun, 13 Jul 2025
Positive week for MacroGenics, Inc. (NASDAQ:MGNX) institutional investors who lost 66% over the past year - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 76.5 (%) |
| Shares Short | 3,560 (K) |
| Shares Short P.Month | 3,730 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | -22 % |
| Operating Margin | -165.3 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -69.8 % |
| Qtrly Rev. Growth | 106 % |
| Gross Profit (p.s.) | -0.26 |
| Sales Per Share | 2.61 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -2.97 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 0.64 |
| Price to Cash Flow | -1.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|